RLX-33

RLX-33 is a potent, selective and blood-brain barrier (BBB) penetrant relaxin family peptide 3 (RXFP3) antagonist, also blocks relaxin-3-induced ERK1/2 phosphorylation, with IC 50 values of 2.36 μM for RXFP3, 7.82 and 13.86 μM for ERK1 and ERK2 phosphorylation, respectively. RLX-33 can block the stimulation of food intake induced by the RXFP3-selective agonist R3/I5 in rats. RLX-33 can be used for the research of metabolic syndrome In Vivo RLX-33 (10 mg/kg; IP, single dosage) attenuates the RXFP3-selective agonist R3/I5-induced increase in feeding in male Wistar rats . RLX-33 (10 mg/kg; IP, single dosage) exhibits a good brain penetration and highly protein-bound in rats plasma . Pharmacokinetic Parameters of RLX-33 in male Wistar rats (IP, 10 mg/kg) . plasma brain C max (ng/mL) 1401 1552 t max (h) 0.5 2.0 t 1/2 (h) 1.9 4.9 AUC inf (ng/mL·h) 5352 12519 CL_F (mL/min/kg) 43.8 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Wistar rats (intracerebroventricular administration of R3/I5 stimulated food intake Dosage: 10 mg/kg Administration: IP, single dosage Result: Attenuated the R3/I5-induced increase in food intake. Animal Model: Male Wistar rats Dosage: 10 mg/kg Administration: IP, single dosage (Pharmacokinetic Analysis) Result: Exhibited a good brain penetration and highly protein-bound, with protein binding of 99.8% in rat plasma. Form:Solid IC50& Target:IC 50 : 2.36 μM (RXFP3), 7.82 μM (ERK1 phosphorylation), 13.86 μM (ERK2 phosphorylation)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet